US20050042194A1 - Semi-solid delivery vehicle and pharmaceutical compositions - Google Patents

Semi-solid delivery vehicle and pharmaceutical compositions Download PDF

Info

Publication number
US20050042194A1
US20050042194A1 US10/953,841 US95384104A US2005042194A1 US 20050042194 A1 US20050042194 A1 US 20050042194A1 US 95384104 A US95384104 A US 95384104A US 2005042194 A1 US2005042194 A1 US 2005042194A1
Authority
US
United States
Prior art keywords
agent
composition
antagonist
polyorthoester
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/953,841
Other languages
English (en)
Inventor
Steven Ng
Hui Shen
Jorge Heller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heron Therapeutics LLC
Original Assignee
AP Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/854,180 external-priority patent/US6613355B2/en
Priority to US10/953,841 priority Critical patent/US20050042194A1/en
Application filed by AP Pharma Inc filed Critical AP Pharma Inc
Publication of US20050042194A1 publication Critical patent/US20050042194A1/en
Priority to EP14192547.9A priority patent/EP2902012B1/de
Priority to EP20176172.3A priority patent/EP3834817A1/de
Priority to EP05802951.3A priority patent/EP1796629B1/de
Priority to EP18187338.1A priority patent/EP3424492B1/de
Priority to ES05802951.3T priority patent/ES2529574T3/es
Priority to KR1020077009728A priority patent/KR20070083851A/ko
Priority to JP2007533786A priority patent/JP2008514646A/ja
Priority to CNA2005800326804A priority patent/CN101052376A/zh
Priority to PCT/US2005/035117 priority patent/WO2006037116A2/en
Priority to CA002579297A priority patent/CA2579297A1/en
Priority to AU2005289425A priority patent/AU2005289425A1/en
Priority to TW094133844A priority patent/TWI407966B/zh
Assigned to A.P. PHARMA, INC. reassignment A.P. PHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NG, STEVEN Y, SHEN, HUI-RONG, HELLER, JORGE
Priority to US12/564,881 priority patent/US8252304B2/en
Priority to US13/279,938 priority patent/US8252305B2/en
Priority to US13/279,949 priority patent/US8252306B2/en
Priority to JP2012045876A priority patent/JP2012107064A/ja
Priority to US13/552,083 priority patent/US8715710B2/en
Assigned to HERON THERAPEUTICS, INC. reassignment HERON THERAPEUTICS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: A.P. PHARMA, INC.
Priority to US14/253,615 priority patent/US20140371187A1/en
Priority to JP2014232639A priority patent/JP6057972B2/ja
Priority to HK16101403.1A priority patent/HK1213477A1/zh
Priority to US15/269,856 priority patent/US9913910B2/en
Priority to JP2016203588A priority patent/JP2017008113A/ja
Priority to US15/897,093 priority patent/US10357570B2/en
Priority to US17/020,464 priority patent/US20200405866A1/en
Priority to US17/240,982 priority patent/US20210252156A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/85—Polyesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
US10/953,841 2000-05-11 2004-09-28 Semi-solid delivery vehicle and pharmaceutical compositions Abandoned US20050042194A1 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
US10/953,841 US20050042194A1 (en) 2000-05-11 2004-09-28 Semi-solid delivery vehicle and pharmaceutical compositions
CA002579297A CA2579297A1 (en) 2004-09-28 2005-09-27 Semi-solid delivery vehicle and pharmaceutical compositions
AU2005289425A AU2005289425A1 (en) 2004-09-28 2005-09-27 Semi-solid delivery vehicle and pharmaceutical compositions
ES05802951.3T ES2529574T3 (es) 2004-09-28 2005-09-27 Vehículo de administración semisólido y composiciones farmacéuticas
CNA2005800326804A CN101052376A (zh) 2004-09-28 2005-09-27 半固体递送载体和药物组合物
EP05802951.3A EP1796629B1 (de) 2004-09-28 2005-09-27 Halbfester abgabeträger und pharmazeutische zusammensetzungen
EP18187338.1A EP3424492B1 (de) 2004-09-28 2005-09-27 Halbfester verabreichungsträger und pharmazeutische zusammensetzungen
EP14192547.9A EP2902012B1 (de) 2004-09-28 2005-09-27 Halbfester Verabreichungsträger und pharmazeutische Zusammensetzung
KR1020077009728A KR20070083851A (ko) 2004-09-28 2005-09-27 반고체 전달 비히클 및 약학 조성물
JP2007533786A JP2008514646A (ja) 2004-09-28 2005-09-27 半固体送達賦形剤および薬学的組成物
EP20176172.3A EP3834817A1 (de) 2004-09-28 2005-09-27 Halbfester verabreichungsträger und pharmazeutische zusammensetzungen
PCT/US2005/035117 WO2006037116A2 (en) 2004-09-28 2005-09-27 Semi-solid delivery vehicle and pharmaceutical compositions
TW094133844A TWI407966B (zh) 2004-09-28 2005-09-28 半固態傳遞媒劑及醫藥組合物
US12/564,881 US8252304B2 (en) 2000-05-11 2009-09-22 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
US13/279,949 US8252306B2 (en) 2000-05-11 2011-10-24 Process for preparing a semi-solid delivery vehicle comprising granisetron
US13/279,938 US8252305B2 (en) 2000-05-11 2011-10-24 Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron
JP2012045876A JP2012107064A (ja) 2004-09-28 2012-03-01 半固体送達賦形剤および薬学的組成物
US13/552,083 US8715710B2 (en) 2004-09-28 2012-07-18 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
US14/253,615 US20140371187A1 (en) 2000-05-11 2014-04-15 Semi-solid delivery vehicle and pharmaceutical compositions
JP2014232639A JP6057972B2 (ja) 2004-09-28 2014-11-17 半固体送達賦形剤および薬学的組成物
HK16101403.1A HK1213477A1 (zh) 2004-09-28 2016-02-05 半固體遞送載體和藥物組合物
US15/269,856 US9913910B2 (en) 2000-05-11 2016-09-19 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
JP2016203588A JP2017008113A (ja) 2004-09-28 2016-10-17 半固体送達賦形剤および薬学的組成物
US15/897,093 US10357570B2 (en) 2004-09-28 2018-02-14 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US17/020,464 US20200405866A1 (en) 2004-09-28 2020-09-14 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US17/240,982 US20210252156A1 (en) 2004-09-28 2021-04-26 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32579000P 2000-05-11 2000-05-11
US09/854,180 US6613355B2 (en) 2000-05-11 2001-05-11 Semi-solid delivery vehicle and pharmaceutical compositions
US10/409,408 US6790458B2 (en) 2000-05-11 2003-04-07 Pharmaceutical compositions using semi-solid delivery vehicle
US10/765,768 US6861068B2 (en) 2000-05-11 2004-01-26 Pharmaceutical compositions using semi-solid delivery vehicle
US10/953,841 US20050042194A1 (en) 2000-05-11 2004-09-28 Semi-solid delivery vehicle and pharmaceutical compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/765,768 Continuation-In-Part US6861068B2 (en) 2000-05-11 2004-01-26 Pharmaceutical compositions using semi-solid delivery vehicle

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/564,881 Continuation US8252304B2 (en) 2000-05-11 2009-09-22 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron

Publications (1)

Publication Number Publication Date
US20050042194A1 true US20050042194A1 (en) 2005-02-24

Family

ID=36119607

Family Applications (10)

Application Number Title Priority Date Filing Date
US10/953,841 Abandoned US20050042194A1 (en) 2000-05-11 2004-09-28 Semi-solid delivery vehicle and pharmaceutical compositions
US12/564,881 Expired - Lifetime US8252304B2 (en) 2000-05-11 2009-09-22 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
US13/279,938 Active US8252305B2 (en) 2000-05-11 2011-10-24 Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron
US13/279,949 Active US8252306B2 (en) 2000-05-11 2011-10-24 Process for preparing a semi-solid delivery vehicle comprising granisetron
US13/552,083 Active US8715710B2 (en) 2000-05-11 2012-07-18 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
US14/253,615 Abandoned US20140371187A1 (en) 2000-05-11 2014-04-15 Semi-solid delivery vehicle and pharmaceutical compositions
US15/269,856 Expired - Lifetime US9913910B2 (en) 2000-05-11 2016-09-19 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US15/897,093 Active US10357570B2 (en) 2004-09-28 2018-02-14 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US17/020,464 Abandoned US20200405866A1 (en) 2004-09-28 2020-09-14 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US17/240,982 Abandoned US20210252156A1 (en) 2004-09-28 2021-04-26 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron

Family Applications After (9)

Application Number Title Priority Date Filing Date
US12/564,881 Expired - Lifetime US8252304B2 (en) 2000-05-11 2009-09-22 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
US13/279,938 Active US8252305B2 (en) 2000-05-11 2011-10-24 Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron
US13/279,949 Active US8252306B2 (en) 2000-05-11 2011-10-24 Process for preparing a semi-solid delivery vehicle comprising granisetron
US13/552,083 Active US8715710B2 (en) 2000-05-11 2012-07-18 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
US14/253,615 Abandoned US20140371187A1 (en) 2000-05-11 2014-04-15 Semi-solid delivery vehicle and pharmaceutical compositions
US15/269,856 Expired - Lifetime US9913910B2 (en) 2000-05-11 2016-09-19 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US15/897,093 Active US10357570B2 (en) 2004-09-28 2018-02-14 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US17/020,464 Abandoned US20200405866A1 (en) 2004-09-28 2020-09-14 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US17/240,982 Abandoned US20210252156A1 (en) 2004-09-28 2021-04-26 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron

Country Status (11)

Country Link
US (10) US20050042194A1 (de)
EP (4) EP3834817A1 (de)
JP (4) JP2008514646A (de)
KR (1) KR20070083851A (de)
CN (1) CN101052376A (de)
AU (1) AU2005289425A1 (de)
CA (1) CA2579297A1 (de)
ES (1) ES2529574T3 (de)
HK (1) HK1213477A1 (de)
TW (1) TWI407966B (de)
WO (1) WO2006037116A2 (de)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264338A1 (en) * 2006-05-12 2007-11-15 Shah Devang T Base-stabilized polyorthoester formulations
US20070264339A1 (en) * 2006-05-12 2007-11-15 Ap Pharma, Inc. Base-stabilized polyorthoester formulations
US20070265329A1 (en) * 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
WO2007138232A2 (fr) * 2006-05-31 2007-12-06 Galderma Research & Development Utilisation du granisetron pour le traitement de sous-types de la rosacée, et compositions pharmaceutiques le contenant
US20080167630A1 (en) * 2004-09-17 2008-07-10 Durect Corporation Controlled delivery system
US20090202436A1 (en) * 2008-04-18 2009-08-13 Medtronic, Inc. Bupivacaine Formulation in a Polyorthoester Carrier
US20090202604A1 (en) * 2008-04-18 2009-08-13 Medtronic, Inc. Benzodiazepine Formulation in a Polyorthoester Carrier
US20090215808A1 (en) * 2007-12-06 2009-08-27 Su Il Yum Oral pharmaceutical dosage forms
US20100010006A1 (en) * 2008-07-08 2010-01-14 Lance William R Pharmaceutical Combination for and Method of Anesthetizing and Immobilizing Non-Domesticated Mammals
US20100152226A1 (en) * 2008-12-11 2010-06-17 Development Center For Biotechnology Sustained release implant for granisetron
US20100260844A1 (en) * 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US7875697B2 (en) 2006-06-29 2011-01-25 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
EP2370064A1 (de) * 2008-12-11 2011-10-05 A.P. Pharma, Inc. Verfahren zur erhöhung der stabilität von polyorthoestern und ihren formulierungen
US8133507B2 (en) 2002-12-13 2012-03-13 Durect Corporation Oral drug delivery system
US20140296282A1 (en) * 2013-03-15 2014-10-02 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems
WO2016044306A1 (en) * 2014-09-15 2016-03-24 Shen Hui Rong Long-acting semi-solid lipid formulations
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9913910B2 (en) 2000-05-11 2018-03-13 Heron Therapeutics, Inc. Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US10201496B2 (en) 2002-06-25 2019-02-12 Durect Corporation Short duration depot formulations
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
US10772871B2 (en) 2013-10-07 2020-09-15 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
US10874642B2 (en) 2013-10-07 2020-12-29 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
US10987342B2 (en) 2013-10-07 2021-04-27 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
US11083796B2 (en) 2005-07-26 2021-08-10 Durect Corporation Peroxide removal from drug delivery vehicle
US11400019B2 (en) 2020-01-13 2022-08-02 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1917971A1 (de) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Zusammensetzungen mit verlängerter Wirkstofffreigabe, enthaltend Polymere mit sehr niedrigem Molekulargewicht
EP2756756B1 (de) * 2008-04-28 2016-01-06 Zogenix, Inc. Neuartige Formulierungen zur Behandlung von Migräne
AU2009270695A1 (en) * 2008-07-17 2010-01-21 Ap Pharma Methods for enhancing the stability of polyorthoesters and their formulations
US20140323517A1 (en) * 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
US10980886B2 (en) 2014-04-21 2021-04-20 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
EP3134068B1 (de) * 2014-04-21 2021-07-21 Heron Therapeutics, Inc. Abgabesysteme langzeitwirkender polymere
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
CN107789628B (zh) * 2016-12-29 2021-07-23 天津键凯科技有限公司 一种聚乙二醇和局部麻醉药的结合物在非麻醉镇痛中的应用
US11162850B2 (en) 2019-04-25 2021-11-02 Measurement Specialties, Inc. Sensor assemblies with integrated electrical connections and diaphragm overload protection
CN113980254A (zh) * 2020-07-10 2022-01-28 南京泛太化工医药研究所 一种具有酸敏感降解、温敏性质的系列聚合物及其载药组合物
CN114366711A (zh) * 2021-12-09 2022-04-19 安徽大学 原酸酯混溶物药用辅料、制备方法、包含该辅料的局部缓释给药制剂
WO2023137659A1 (zh) * 2022-01-20 2023-07-27 南京泛太化工医药研究所 一种具有酸敏感降解、温敏性质的系列聚合物及其载药组合物

Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4098709A (en) * 1975-12-11 1978-07-04 Rohm And Haas Company Polymeric antioxidant viscosity index improvers
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4322323A (en) * 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
US4343787A (en) * 1975-07-29 1982-08-10 Merck & Co., Inc. Shaped ophthalmic inserts for treating dry eye syndrome
US4532335A (en) * 1983-03-07 1985-07-30 Sri International Preparation of ketene acetals by rearrangement of allyl and substituted allyl acetals
US4549010A (en) * 1984-06-27 1985-10-22 Merck & Co., Inc. Bioerodible poly(ortho ester) thermoplastic elastomer from diketene diacetal
US4745160A (en) * 1984-06-26 1988-05-17 Imperial Chemical Industries Plc Biodegradable amphipathic copolymers
US4946931A (en) * 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
US5540912A (en) * 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US5607686A (en) * 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
US5690059A (en) * 1996-04-16 1997-11-25 Woods; Jeff Training collar
US5759563A (en) * 1994-04-08 1998-06-02 Atrix Laboratories, Inc. Liquid delivery compositions
US5840336A (en) * 1992-10-05 1998-11-24 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5873228A (en) * 1996-05-09 1999-02-23 Kuhn S.A. Shredder for plants
US5929059A (en) * 1991-01-19 1999-07-27 Smithkline Beecham P.L.C. Pharmaceutical compositions containing granisetron and dexamethasone
US5939453A (en) * 1998-06-04 1999-08-17 Advanced Polymer Systems, Inc. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6372245B1 (en) * 1992-12-29 2002-04-16 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
US20020176844A1 (en) * 2001-05-11 2002-11-28 Ng Steven Y. Bioerodible polyorthoesters containing hydrogen bonding groups
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US6613355B2 (en) * 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20040037885A1 (en) * 2000-12-07 2004-02-26 Min-Hyo Seo Composition for sustained delivery of hydrophobic drugs and process for the preparation thereof
US6699500B2 (en) * 1996-10-31 2004-03-02 Takeda Chemical Industries, Ltd. Sustained-release preparation capable of releasing a physiologically active substance

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT75625B (en) 1981-10-08 1985-12-09 Merck & Co Inc Process for preparing biosoluble ocular insert
IL96486A (en) * 1989-11-28 1995-03-30 Syntex Inc Preparation tricyclic compounds and pharmaceutical preparations containing them
NZ239370A (en) * 1990-08-22 1994-04-27 Merck & Co Inc Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone
PT99989A (pt) 1991-01-09 1994-05-31 Alza Corp Dispositivos biodegradaveis e composicoes para libertacao difusivel de agentes
EP0633907A1 (de) 1992-03-30 1995-01-18 Alza Corporation Additive für bioerodierbare polymere um die abbau zu regulieren
AU4406793A (en) * 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
ATE194489T1 (de) 1992-12-29 2000-07-15 Insite Vision Inc Bioerodierbares system zur kontrollierten freigabe
GB9412995D0 (en) * 1994-06-28 1994-10-26 Prendergast Kenneth F Safety enhancing pharmaceutical compositions of an active indazole
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
AU1527097A (en) 1996-01-05 1997-08-01 Advanced Polymer Systems Inc. Polymers with controlled physical state and bioerodibility
JP2000510153A (ja) 1996-06-21 2000-08-08 メルク シヤープ エンド ドーム リミテツド スピロ―ピペリジン誘導体及び該誘導体の治療薬としての使用
AU3170697A (en) 1997-05-30 1998-12-30 Minnesota Mining And Manufacturing Company Transdermal drug delivery device for the delivery of tropisetron or granisetron
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
AU2001261516A1 (en) * 2000-05-11 2001-11-20 Advanced Polymer Systems Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20050042194A1 (en) * 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
IL153563A0 (en) 2000-07-18 2003-07-06 Leo Pharma As Matrix metalloproteinase inhibitors
US6590059B2 (en) * 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
FR2826280B1 (fr) 2001-06-20 2005-03-04 Ceva Sante Animale Composition semi-solide injectable biodegradable assurant un profil de liberation particulier
US8252303B2 (en) * 2002-07-31 2012-08-28 Durect Corporation Injectable depot compositions and uses thereof
WO2004011054A2 (en) * 2002-07-31 2004-02-05 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
BR0315304A (pt) * 2002-11-06 2005-08-16 Alza Corp Formulações com depósito para liberação controlada
US7045589B2 (en) * 2002-11-15 2006-05-16 A.P. Pharma, Inc. Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
CN101426529A (zh) * 2005-03-31 2009-05-06 阿帕医药有限公司 Peg-聚（原酸酯）接枝共聚物和药物组合物
AU2006230247A1 (en) * 2005-03-31 2006-10-05 A.P. Pharma, Inc. PEG-polyacetal and PEG-polyacetal-POE graft copolymers and pharmaceutical compositions
US20070264339A1 (en) 2006-05-12 2007-11-15 Ap Pharma, Inc. Base-stabilized polyorthoester formulations

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4138344A (en) * 1975-01-28 1979-02-06 Alza Corporation Erodible agent releasing device comprising poly(orthoesters) and poly(orthocarbonates)
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4343787A (en) * 1975-07-29 1982-08-10 Merck & Co., Inc. Shaped ophthalmic inserts for treating dry eye syndrome
US4098709A (en) * 1975-12-11 1978-07-04 Rohm And Haas Company Polymeric antioxidant viscosity index improvers
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4322323A (en) * 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
US4532335A (en) * 1983-03-07 1985-07-30 Sri International Preparation of ketene acetals by rearrangement of allyl and substituted allyl acetals
US4745160A (en) * 1984-06-26 1988-05-17 Imperial Chemical Industries Plc Biodegradable amphipathic copolymers
US4549010A (en) * 1984-06-27 1985-10-22 Merck & Co., Inc. Bioerodible poly(ortho ester) thermoplastic elastomer from diketene diacetal
US4946931A (en) * 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
US5929059A (en) * 1991-01-19 1999-07-27 Smithkline Beecham P.L.C. Pharmaceutical compositions containing granisetron and dexamethasone
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
US5540912A (en) * 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US5840336A (en) * 1992-10-05 1998-11-24 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US6372245B1 (en) * 1992-12-29 2002-04-16 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
US5759563A (en) * 1994-04-08 1998-06-02 Atrix Laboratories, Inc. Liquid delivery compositions
US5607686A (en) * 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US5690059A (en) * 1996-04-16 1997-11-25 Woods; Jeff Training collar
US5873228A (en) * 1996-05-09 1999-02-23 Kuhn S.A. Shredder for plants
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US6699500B2 (en) * 1996-10-31 2004-03-02 Takeda Chemical Industries, Ltd. Sustained-release preparation capable of releasing a physiologically active substance
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US5939453A (en) * 1998-06-04 1999-08-17 Advanced Polymer Systems, Inc. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6613355B2 (en) * 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6790458B2 (en) * 2000-05-11 2004-09-14 Ap Pharma Inc. Pharmaceutical compositions using semi-solid delivery vehicle
US6861068B2 (en) * 2000-05-11 2005-03-01 A.P. Pharma, Inc. Pharmaceutical compositions using semi-solid delivery vehicle
US20040037885A1 (en) * 2000-12-07 2004-02-26 Min-Hyo Seo Composition for sustained delivery of hydrophobic drugs and process for the preparation thereof
US20020176844A1 (en) * 2001-05-11 2002-11-28 Ng Steven Y. Bioerodible polyorthoesters containing hydrogen bonding groups
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913910B2 (en) 2000-05-11 2018-03-13 Heron Therapeutics, Inc. Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US11179326B2 (en) 2002-06-25 2021-11-23 Durect Corporation Short duration depot formulations
US10471002B2 (en) 2002-06-25 2019-11-12 Durect Corporation Short duration depot formulations
US10471001B2 (en) 2002-06-25 2019-11-12 Durect Corporation Short duration depot formulations
US10201496B2 (en) 2002-06-25 2019-02-12 Durect Corporation Short duration depot formulations
US8951556B2 (en) 2002-12-13 2015-02-10 Durect Corporation Oral drug delivery system
US8420120B2 (en) 2002-12-13 2013-04-16 Durect Corporation Oral drug delivery system
US8153152B2 (en) 2002-12-13 2012-04-10 Durect Corporation Oral drug delivery system
US8147870B2 (en) 2002-12-13 2012-04-03 Durect Corporation Oral drug delivery system
US8133507B2 (en) 2002-12-13 2012-03-13 Durect Corporation Oral drug delivery system
US8974821B2 (en) 2002-12-13 2015-03-10 Durect Corporation Oral drug delivery system
US8168217B2 (en) 2002-12-13 2012-05-01 Durect Corporation Oral drug delivery system
US9918982B2 (en) 2002-12-13 2018-03-20 Durect Corporation Oral drug delivery system
US9517271B2 (en) 2002-12-13 2016-12-13 Durect Corporation Oral drug delivery system
US9233160B2 (en) 2002-12-13 2016-01-12 Durect Corporation Oral drug delivery system
US8945614B2 (en) 2002-12-13 2015-02-03 Durect Corporation Oral drug delivery system
US8354124B2 (en) 2002-12-13 2013-01-15 Durect Corporation Oral drug delivery system
US8846072B2 (en) 2004-09-17 2014-09-30 Durect Corporation Controlled delivery system
US20110009451A1 (en) * 2004-09-17 2011-01-13 Neil A Verity Controlled delivery system
US8753665B2 (en) 2004-09-17 2014-06-17 Durect Corporation Controlled delivery system
US8153661B2 (en) 2004-09-17 2012-04-10 Durect Corporation Controlled delivery system
US8153149B2 (en) 2004-09-17 2012-04-10 Durect Corporation Controlled delivery system
US20090036490A1 (en) * 2004-09-17 2009-02-05 Durect Corporation Controlled delivery system
US20080167630A1 (en) * 2004-09-17 2008-07-10 Durect Corporation Controlled delivery system
US10357570B2 (en) 2004-09-28 2019-07-23 Heron Therapeutics, Inc. Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US11083796B2 (en) 2005-07-26 2021-08-10 Durect Corporation Peroxide removal from drug delivery vehicle
US20080015210A1 (en) * 2006-05-12 2008-01-17 Devang Shah Base-Stabilized Polyorthoester Formulations
US20070265329A1 (en) * 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US20070264338A1 (en) * 2006-05-12 2007-11-15 Shah Devang T Base-stabilized polyorthoester formulations
US20070264339A1 (en) * 2006-05-12 2007-11-15 Ap Pharma, Inc. Base-stabilized polyorthoester formulations
FR2901702A1 (fr) * 2006-05-31 2007-12-07 Galderma Res & Dev S N C Snc Utilisation de granisetron pour le traitement de sous-types de la rosacee, et compositions pharmaceutiques
WO2007138232A3 (fr) * 2006-05-31 2008-03-27 Galderma Res & Dev Utilisation du granisetron pour le traitement de sous-types de la rosacée, et compositions pharmaceutiques le contenant
WO2007138232A2 (fr) * 2006-05-31 2007-12-06 Galderma Research & Development Utilisation du granisetron pour le traitement de sous-types de la rosacée, et compositions pharmaceutiques le contenant
US7875697B2 (en) 2006-06-29 2011-01-25 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
US20110082275A1 (en) * 2006-06-29 2011-04-07 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
US8133968B2 (en) 2006-06-29 2012-03-13 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems
US8415401B2 (en) 2007-12-06 2013-04-09 Durect Corporation Oral pharmaceutical dosage forms
US9655861B2 (en) 2007-12-06 2017-05-23 Durect Corporation Oral pharmaceutical dosage forms
US9592204B2 (en) 2007-12-06 2017-03-14 Durect Corporation Oral pharmaceutical dosage forms
US20090298862A1 (en) * 2007-12-06 2009-12-03 Su Il Yum Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition
US20090215808A1 (en) * 2007-12-06 2009-08-27 Su Il Yum Oral pharmaceutical dosage forms
US10206883B2 (en) 2007-12-06 2019-02-19 Durect Corporation Oral pharamaceutical dosage forms
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US20090208554A1 (en) * 2008-04-18 2009-08-20 Medtronic, Inc. Baclofen Formulation in a Polyorthoester Carrier
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
US20090202604A1 (en) * 2008-04-18 2009-08-13 Medtronic, Inc. Benzodiazepine Formulation in a Polyorthoester Carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US20090202436A1 (en) * 2008-04-18 2009-08-13 Medtronic, Inc. Bupivacaine Formulation in a Polyorthoester Carrier
US20100010006A1 (en) * 2008-07-08 2010-01-14 Lance William R Pharmaceutical Combination for and Method of Anesthetizing and Immobilizing Non-Domesticated Mammals
US7795263B2 (en) 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US10328068B2 (en) 2008-11-03 2019-06-25 Durect Corporation Oral pharmaceutical dosage forms
US20100260844A1 (en) * 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9884056B2 (en) 2008-11-03 2018-02-06 Durect Corporation Oral pharmaceutical dosage forms
US9616055B2 (en) 2008-11-03 2017-04-11 Durect Corporation Oral pharmaceutical dosage forms
EP2370064A1 (de) * 2008-12-11 2011-10-05 A.P. Pharma, Inc. Verfahren zur erhöhung der stabilität von polyorthoestern und ihren formulierungen
EP2370064A4 (de) * 2008-12-11 2012-09-19 A P Pharma Inc Verfahren zur erhöhung der stabilität von polyorthoestern und ihren formulierungen
US8835453B2 (en) 2008-12-11 2014-09-16 Development Center For Biotechnology Sustained release implant for granisetron
US20100152226A1 (en) * 2008-12-11 2010-06-17 Development Center For Biotechnology Sustained release implant for granisetron
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN111956598A (zh) * 2013-03-15 2020-11-20 赫伦治疗有限公司 聚原酸酯和质子惰性溶剂的组合物
US11253504B2 (en) 2013-03-15 2022-02-22 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US9446036B2 (en) * 2013-03-15 2016-09-20 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US10300142B2 (en) 2013-03-15 2019-05-28 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9744163B2 (en) 2013-03-15 2017-08-29 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US9913909B2 (en) 2013-03-15 2018-03-13 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US10398686B2 (en) 2013-03-15 2019-09-03 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US20140296282A1 (en) * 2013-03-15 2014-10-02 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US9907851B2 (en) 2013-03-15 2018-03-06 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9855333B2 (en) 2013-03-15 2018-01-02 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US10772871B2 (en) 2013-10-07 2020-09-15 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
US10874642B2 (en) 2013-10-07 2020-12-29 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
US10987342B2 (en) 2013-10-07 2021-04-27 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
WO2016044306A1 (en) * 2014-09-15 2016-03-24 Shen Hui Rong Long-acting semi-solid lipid formulations
US9849180B2 (en) 2014-09-15 2017-12-26 Hui Rong Shen Long-acting semi-solid lipid formulations
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
US11400019B2 (en) 2020-01-13 2022-08-02 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11771624B2 (en) 2020-01-13 2023-10-03 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Also Published As

Publication number Publication date
EP1796629A4 (de) 2013-01-09
EP2902012A1 (de) 2015-08-05
US20180339052A1 (en) 2018-11-29
US10357570B2 (en) 2019-07-23
US20210252156A1 (en) 2021-08-19
US20120041020A1 (en) 2012-02-16
US8252305B2 (en) 2012-08-28
US20120283253A1 (en) 2012-11-08
HK1213477A1 (zh) 2016-07-08
US8715710B2 (en) 2014-05-06
TWI407966B (zh) 2013-09-11
JP2015034182A (ja) 2015-02-19
EP3834817A1 (de) 2021-06-16
CA2579297A1 (en) 2006-04-06
JP2017008113A (ja) 2017-01-12
TW200616650A (en) 2006-06-01
WO2006037116A3 (en) 2006-06-01
ES2529574T3 (es) 2015-02-23
US20200405866A1 (en) 2020-12-31
EP1796629A2 (de) 2007-06-20
US9913910B2 (en) 2018-03-13
EP2902012B1 (de) 2018-08-08
US20140371187A1 (en) 2014-12-18
US8252306B2 (en) 2012-08-28
US20170007705A1 (en) 2017-01-12
CN101052376A (zh) 2007-10-10
US20100010104A1 (en) 2010-01-14
EP1796629B1 (de) 2014-11-12
WO2006037116A2 (en) 2006-04-06
JP2012107064A (ja) 2012-06-07
US8252304B2 (en) 2012-08-28
US20120041021A1 (en) 2012-02-16
EP3424492B1 (de) 2020-05-27
AU2005289425A1 (en) 2006-04-06
EP3424492A1 (de) 2019-01-09
JP6057972B2 (ja) 2017-01-11
AU2005289425A2 (en) 2006-04-06
JP2008514646A (ja) 2008-05-08
KR20070083851A (ko) 2007-08-24

Similar Documents

Publication Publication Date Title
US10357570B2 (en) Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
US6861068B2 (en) Pharmaceutical compositions using semi-solid delivery vehicle
US20070264339A1 (en) Base-stabilized polyorthoester formulations
US20080015210A1 (en) Base-Stabilized Polyorthoester Formulations
EP1280558B1 (de) Halbfester verabreichungsträger und arzneimittel
AU2006230226A1 (en) PEG-poly(ortho ester) graft copolymers and pharmaceutical compositions
AU2006230201A1 (en) PEG-polyacetal diblock and triblock copolymers and pharmaceutical compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: A.P. PHARMA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NG, STEVEN Y;SHEN, HUI-RONG;HELLER, JORGE;REEL/FRAME:022050/0232;SIGNING DATES FROM 20080829 TO 20081030

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION

AS Assignment

Owner name: HERON THERAPEUTICS, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:A.P. PHARMA, INC.;REEL/FRAME:032153/0273

Effective date: 20140109